We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Antibodies Provide Clues to Transplant Rejection Risk

By LabMedica International staff writers
Posted on 09 Sep 2015
Print article
The INNO-LiPA HLA-B Update Plus line probe assay for the molecular typing of human leukocyte antigen (HLA) B alleles at allele group level
The INNO-LiPA HLA-B Update Plus line probe assay for the molecular typing of human leukocyte antigen (HLA) B alleles at allele group level (Photo courtesy of FUJIREBIO)
The dominant antibody type present in the blood of transplant recipients may indicate their likelihood of experiencing organ rejection, and this may help doctors identify patients who need aggressive treatments to safeguard the health of their new organ.

Transplant recipients who receive a kidney, heart, or lung often develop an immune response to the foreign tissue in the form of antibodies referred as donor-specific Human Leukocyte Antigen (HLA) antibodies. Some patients may already have these antibodies before their transplant because they have been exposed to blood products or previous transplants.

An international collaborating team of scientists led by those at Saint-Louis Hospital (Paris, France) designed a study to determine the greatest risk for losing a transplanted organ based on the characteristics and function of donor-specific HLA antibodies. Their study included 125 kidney transplant patients with donor-specific anti-HLA antibodies detected in the first year post-transplant. Renal tissue from the biopsies was fixed in acetic-formol-absolute alcohol fixative and stained with Masson’s trichrome and periodic acid–Schiff. All of the graft biopsies were scored and graded from 0 to 3.

All kidney transplant recipients were tested for circulating donor specific anti-HLA-A, -B, -Cw, -DR, -DQ, and –DP antibodies in serum samples obtained one year after transplantation or during an episode of acute rejection within one year after transplantation. Single-antigen flow bead assays (One Lambda, Inc.; Canoga Park, CA, USA) were used on a Luminex platform. HLA typing of the recipients was performed by INNO-LiPA HLA typing kit (Innogenetics; Gent, Belgium). For all kidney transplant donors, tissue typing was initially performed using the microlymphocytotoxicity technique with tissue typing trays at transplantation and was confirmed by molecular biology.

The investigators found that the presence of certain donor-specific HLA antibodies, namely immunoglobulin G3 (IgG3) and IgG4 subclasses correlated with distinct patterns of antibody-mediated injury to the transplanted organ. Patients with mostly IgG3 donor-specific HLA antibodies had a higher likelihood of organ rejection soon after transplantation. If rejection occurred in those with mostly IgG4 antibodies, it was usually much later after transplantation.

Carmen Lefaucheur, MD, PhD, the lead author of the study, said, “Our clinical investigation may help in the future to identify the patients that will require interventions to prevent the loss of a transplanted organ. Also, based on what we learned in this investigation, more studies will be initiated to further elucidate why some patients seem to maintain good outcomes while others demonstrate accelerated deterioration of the transplanted kidney in the presence of circulating donor-specific HLA antibodies.” The study was published on August 20, 2015, in the Journal of the American Society of Nephrology.

Related Links:

Saint-Louis Hospital
One Lambda Inc. 
Innogenetics  


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.